Skip to main content
. Author manuscript; available in PMC: 2015 Feb 3.
Published in final edited form as: J Surg Oncol. 2011 Sep 6;105(4):431–435. doi: 10.1002/jso.22093

Figure 4.

Figure 4

Activated TDLN B cells produce antibody that can mediate complement dependent cytotoxicity (CDC). Supernatants (Sup) from activation cultures of D5 and MCA 205 TDLN B cells were tested for their ability to mediate CDC in vitro. Pan-02 was used as an irrelevant tumor cell control. As can be seen, the supernatants contained antibodies that were able to specifically lyse the relevant tumor targets. (Li et al.)39